Medimmune to pay Medarex $15 mln in collaboration
Tue Nov 23, 2004 08:15 AM ET
CHICAGO, Nov 23 (Reuters) - MedImmune Inc.(MEDI.O: Quote, Profile, Research) , which makes a nasal spray flu vaccine, said on Tuesday it will pay biotechnology company Medarex Inc.(MEDX.O: Quote, Profile, Research) $15 million as part of a drug development collaboration aimed at developing antibodies to treat diseases of the immune system.
The companies said the collaboration will focus on two antibodies, MDX-1103 and MDX-1333, that are currently in preclinical development by Medarex for the treatment of autoimmune diseases, such as lupus.
Under the terms of the agreement, MedImmune will be fully responsible for the continued development of the product candidates.
Also, a conference call:
PRINCETON, N.J., Nov. 23 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) is scheduled to host a conference call and live audio webcast today at 10:00 a.m. Eastern time to discuss its collaboration for fully human antibodies for autoimmune diseases with MedImmune, Inc. To access the call live, please dial 800-798-2884 within the U.S. or 617-614-6207 outside of the U.S. and enter passcode 99331245. The call will also be broadcast live via the Internet at medarex.com.
The webcast will be available on the Events page in the Investor Relations section of Medarex's website at medarex.com and will be archived for a limited time following the webcast. To access the archive, please dial 888-286-8010 within the U.S. or 617-801-6888 outside the U.S. and enter passcode 39740512. |
